Triple Therapy Linked to Mortality Rate in CAD With GI Bleeding

December 06, 2017

Increased mortality at 90 days in patients with lower gastrointestinal bleeding, coronary artery disease

Should Antithrombotics Be Stopped Before Wide-Awake CTR Surgery?

December 05, 2017

Ninety-three of the 99 patients taking AT medication continued their normal regimen through surgery and were included in the analysis.

First PCSK9 Inhibitor Gets FDA Approval for MI, Stroke Prevention

By December 04, 2017

Repatha reduced the risk of heart attack by 27%, the risk of stroke by 21% and the risk of coronary revascularization by 22%.

Patient Admitted Eleven Times for Hypertriglyceridemia-Induced Pancreatitis

By December 01, 2017

The patient was was admitted eleven times over seven years for hypertriglyceridemia-induced pancreatitis.

Is One Statin More Likely to Increase Myopathy Risk Over Another?

By November 14, 2017

Myopathy is frequently cited as a reason for statin therapy cessation.

Statin Use May Up Diabetes Risk in Higher Risk Patients

October 24, 2017

Researchers assessed incident diabetes by annual 75g oral glucose tolerance testing and semiannual fasting glucose among 3,234 participants enrolled in the Diabetes Prevention Program Outcomes Study.

Merck Decides to Put the Brakes on CETP Inhibitor Anacetrapib

By October 13, 2017

The decision follows a review of the clinical profile and discussions with external experts

Better Risk Factor Modification Strategies Needed for Optimal Stroke Prevention

October 12, 2017

Increases in prevalence of hypertension, diabetes, dyslipidemia, smoking, and drug abuse in AIS

PCSK9i Prescription Approval, Abandonment Rate in First Year of Availability

September 28, 2017

The researchers found that 20.8% of patients given a prescription received approval on the first day and that 47.2% ever received approval.

Increased Med Use Over Time Seen in Older Patients of All BMI Classes

By September 22, 2017

Researchers aimed to determine whether the rise in prescription drug use over time varied by age and obesity status.

Effects of Anagliptin vs. Alogliptin on Lipid Profile of T2D Patients

September 19, 2017

The researchers found that there was no significant difference in percent change in LDL-C level between the 2 groups at 24 weeks.

Effects of Statin Use as Primary Prevention Examined in Older Males

September 18, 2017

The researchers found that over the study period statin use was associated with an 18% lower risk of all-cause mortality and non-significantly lower risk of CVD events and stroke.

Evolocumab Safe, Effective in Patients with Diabetes

By September 15, 2017

Compared to placebo, Repatha was not associated with an increased risk of developing new-onset diabetes or worsening glycemia over a median follow-up period of 2.2 years in patients without diabetes at baseline.

Statin Use May Reduce Mortality Risk in COPD

September 08, 2017

Statin exposure associated with lower all-cause, pulmonary mortality

Statins May Lower the Risk of Premature Death in Alcoholic Cirrhosis

By September 08, 2017

Results found that mortality rates were 88 (95% CI; 73-105) per 1,000 years for patients using statins and 127 (95% CI; 114-141) for non-statin patients, the hazard ratio was 0.57 (95% CI; 0.41-0.71).

Updated Storage Information for Praluent

By September 07, 2017

Previously, time out of refrigeration was not to exceed 24 hours at 77ºF.

Link Between Cardiovascular Med Use and Cognitive Impairment Explored

September 01, 2017

No link for impaired cognition, antihypertensive, antithrombotic, lipid-modifying agent use

Does Lowering LDL-C to Ultra-Low Levels Provide Additional Benefit?

By September 01, 2017

The researchers observed these endpoints according to degree of LDL cholesterol reduction after 1 month of treatment.

Familial Chylomicronemia Syndrome Treatment to Get FDA Review

By August 31, 2017

A total of 66 patients with FCS were enrolled in the year-long APPROACH which met its primary endpoint of reduction in triglycerides at 3 months, with a 77% mean reduction in triglycerides for volanesorsen-treated patients.

Anacetrapib Efficacy Examined in Patients with Atherosclerotic Vascular Disease

August 30, 2017

Participants were randomized to 100mg of anacetrapib once daily or matching placebo.

Carbs More Likely to Kill than Fats, Says New Study

August 30, 2017

The investigators found that high-carbohydrate diets are common, with more than half of the people deriving 70 percent of their daily calories from carbs.

Clinical Benefit of Lowering LDL-C May Depend on How It Is Lowered

August 29, 2017

Change in apoB levels may be better predictor of clinical response than LDL-C, HDL-C levels

Timing of Administration Important for Some, But Not All Statins

By August 23, 2017

Statins, or HMG-CoA reductase inhibitors, are considered a standard therapy for many types of dyslipidemia and are generally "administered in the evening because cholesterol biosynthesis peaks during the night and also because most of them (simvastatin, pravastatin, fluvastatin, and lovastatin) have short half-lives."

Does Adding Evolocumab to Statin Tx Impact Cognitive Function?

August 17, 2017

The researchers found that the mean change from baseline over time in the raw score for the spatial working memory strategy index of executive function was −0.21 ± 2.62 and −0.29 ± 2.81 in the evolocumab and placebo groups, respectively.

Recall: Antidepressant Tablets Found in Bottle Labeled for Cholesterol Med

By August 10, 2017

While side effects of bupropion are typically minor, some patients may be at greater risk for adverse effects.

Nikita Approved to Treat Primary Hyperlipidemia, Mixed Dyslipidemia

By August 09, 2017

The efficacy of pitavastatin has been evaluated in multiple clinical studies.

Obeticholic Acid + Statin Shows Rapid Reversal of LDL Rise in NASH Patients

By August 02, 2017

The mean LDL change from baseline to Week 16 were as follows: placebo: -48 mg/dL, OCA 5mg: -40mg/dL, OCA 10mg: -40mg/dL, and OCA 25mg: -45mg/dL.

Repatha sBLA Under Priority Review for MACE Risk Reduction

By July 28, 2017

Results showed that the evolocumab group had a statistically significant 15% reduction (P<0.001) in the risk of extended MACE composite (primary) endpoint - which included hospitalization for unstable angina, coronary revascularization, heart attack, stroke or cardiovascular death - compared to placebo group.

Should Children with Familial Hypercholesterolemia Receive Statins?

By July 27, 2017

The researchers found that statins reduced the mean low-density lipoprotein (LDL) cholesterol concentration at all time points (moderate quality evidence).